🔴 Novo Nordisk is trading 6.2% down in pre-market as investors seek clearer growth plans beyond Wegovy

Novo Nordisk is trading 6.2% down now at $40.58 (-6.15%) as investors seek clearer plans to restore growth beyond Wegovy and compete with Eli Lilly.

• Management will present strategy, pipeline, operations, and performance updates in London at its September 21, 2026 Capital Markets Day.
• The broader market is higher, suggesting company-specific uncertainty is outweighing risk-on sentiment.